Drug Landscape ›
TERLIPRESSIN ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 204
Most-reported reactions
Drug Ineffective — 38 reports (18.63%) Electrocardiogram Qt Prolonged — 23 reports (11.27%) Renal Impairment — 22 reports (10.78%) Ascites — 19 reports (9.31%) Off Label Use — 19 reports (9.31%) Hepatic Encephalopathy — 18 reports (8.82%) Multiple Organ Dysfunction Syndrome — 18 reports (8.82%) Diarrhoea — 16 reports (7.84%) Toxicity To Various Agents — 16 reports (7.84%) Product Use In Unapproved Indication — 15 reports (7.35%)
Source database →
TERLIPRESSIN in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is TERLIPRESSIN approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for TERLIPRESSIN in United States?
Marketing authorisation holder not available in our data.